0000950170-24-109448.txt : 20240925 0000950170-24-109448.hdr.sgml : 20240925 20240925202915 ACCESSION NUMBER: 0000950170-24-109448 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240925 FILED AS OF DATE: 20240925 DATE AS OF CHANGE: 20240925 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Karlin Dan CENTRAL INDEX KEY: 0001897618 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40360 FILM NUMBER: 241325969 MAIL ADDRESS: STREET 1: C/O MIND MEDICINE INC. STREET 2: ONE WORLD TRADE CENTER, SUITE 8500 CITY: NEW YORK STATE: NY ZIP: 10007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Mind Medicine (MindMed) Inc. CENTRAL INDEX KEY: 0001813814 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE WORLD TRADE CENTER STREET 2: SUITE 8500 CITY: NEW YORK STATE: NY ZIP: 10007 BUSINESS PHONE: 212-220-6633 MAIL ADDRESS: STREET 1: ONE WORLD TRADE CENTER STREET 2: SUITE 8500 CITY: NEW YORK STATE: NY ZIP: 10007 4 1 ownership.xml 4 X0508 4 2024-09-25 0001813814 Mind Medicine (MindMed) Inc. MNMD 0001897618 Karlin Dan C/O MIND MEDICINE (MINDMED) INC. ONE WORLD TRADE CENTER, SUITE 8500 NEW YORK NY 10007 false true false false Chief Medical Officer true Common Shares 2024-09-25 4 S false 6871 5.98 D 344656 D Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 14, 2022. The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 25, 2024 at prices ranging from $5.95 to $6.07. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. /s/Mark Sullivan, Attorney-in-Fact for Dan Karlin 2024-09-25